ted

ents

nd

use

In This Issue of JAMA

Research

Corticosteroids for Severe Community-Acquired Pneumonia

In a randomized placebo-controlled trial that enrolled 120 patients with severe community-acquired pneumonia and evidence of a high inflammatory response at hospital admission, Torres and colleagues assessed the effect of adjunctive therapy with corticosteroids on treatment failure. The authors report that compared with placebo, acute use of intravenous methylprednisolone decreased the risk of treatment failure. In an Editorial, Wunderink discusses appropriate use of corticosteroids in patients with severe community-acquired pneumonia.


Editorial 673

Author Audio Interview jama.com

Varenicline for Smoking Cessation Through Reduction

687

677



Ebbert and colleagues assessed the efficacy and safety of varenicline for increasing smoking abstinence rates through smoking reduction in a multicenter trial that enrolled 1510 individuals not willing or able to quit smoking in the next month but willing to reduce smoking and make a quit attempt within 3 months of study enrollment. Participants were randomly assigned to receive varenicline or placebo for 24 weeks.

The authors found that compared with placebo-assigned participants, those who received varenicline for 24 weeks had significantly increased smoking abstinence rates at 1 year.

Author Video Interview jama.com Continuing Medical Education jamanetworkcme.com

Eliglustat for Splenomegaly in Gaucher Disease

Standard treatment of Gaucher disease type 1 requires lifelong, biweekly, intravenous infusions of enzyme replacement therapy. In a randomized placebo-controlled trial that enrolled 40 adults with untreated Gaucher disease type 1, Mistry and colleagues investigated the efficacy of eliglustat-a novel oral substrate-reduction therapy-on clinical manifestations of the disease. The authors report that compared with placebo, 9 months' treatment with eliglustat resulted in reductions in spleen volume and improvements in hemoglobin level, liver volume, and platelet count.

Opinion Viewpoint

663 Stealth Research: Is Biomedical Innovation Happening Outside the Peer-Reviewed Literature? JPA loannidis

665 In Defense of the Employer Mandate: Hedging Against Uninsurance JE McDonough and EY Adashi

667 FDA Regulation of Laboratory-Developed Diagnostic Tests: Protect the Public, Advance the Science J Sharfstein

669 Genetic Testing and FDA Regulation: Overregulation Threatens the Emergence of Genomic Medicine JP Evans and MS Watson

A Piece of My Mind

671 The Other AMA DF Chen

Editorial

673 Corticosteroids for Severe Community-Acquired Pneumonia: Not for Everyone **RG** Wunderink

675 To JAMA Authors, Peer Reviewers. and Readers-Thank You H Bauchner, PB Fontanarosa. and RM Golub

LETTERS

Research Letter

724 Heart Rate and Body Temperature Responses to Extreme Heat and Humidity With and Without Electric Fans NM Ravanelli and Coauthors

Comment & Response

725 Fecal Microbiota Transplantation for Clostridium difficile Infection

727 Adapting to Climate Change

728 Goals of Displaying Health Care Prices to Physicians

729 Correction

Editor in Chief Howard Bauchner, MD

131 YEARS OF CONTINUOUS PUBLICATION



In This Issue of JAMA

February 17, 2015 Volume 313, Number 7 Pages 641-764

Research (continued)

Fondaparinux vs LMWH in Patients with NSTEMI

A clinical trial involving patients with non-ST-segment elevation myocardial infarction (NSTEMI) found fondaparinux to be noninferior to low-molecular-weight heparin (LMWH) in reducing ischemic outcomes, with fewer severe bleeding events in the fondaparinux group. In an analysis of Swedish registry data from 40 616 consecutive patients with NSTEMI treated with either fondaparinux or LMWH, Szummer and colleagues found that fondaparinux was associated with lower risk of major bleeding events and death both inhospital and through 180 days of follow-up and had similar rates of recurrent myocardial infarction and stroke.

Clinical Review & Education

Starting a New Discussion About Lung Cancer Screening

An article in *JAMA Internal Medicine* reported that more than 18% of lung cancers detected with low-dose computed tomography screening in the National Lung Cancer Screening Trial were probably indolent and unlikely to cause clinical symptoms. In this From The JAMA Network article, Harris encourages open discussion of the benefits, harms, and costs of wide-scale screening for lung cancer and discusses the role of screening in reducing lung cancer deaths.

Use of Pneumococcal Vaccine in Adults

This JAMA Clinical Guidelines Synopsis article by Pisano and Cifu summarizes the 2014 Advisory Committee for Immunization Practices recommendations for use of pneumococcal vaccine in adults. Among the recommendations is that all adults aged 65 years or older should receive the 13-valent pneumococcal conjugate vaccine in series with the 23-valent pneumococcal polysaccharide vaccine.

Shortness of Breath After a Choking Incident

A 67-year-old woman presented to the emergency department with dyspnea and in respiratory distress. Two hours prior, she choked while eating, and the Heimlich maneuver successfully dislodged a piece of food. A chest radiograph and computed tomographic scan of the chest were obtained. What would you do next?

■ Quiz jama.com

707

719

721



JAMA Patient Page 758 Pneumococcal Vaccination

NEWS & ANALYSIS

Medical News & Perspectives

654 Researchers Look to MRI and Biomarkers to Help Improve Detection of Aggressive Prostate Cancers

657 Choosing Wisely: Changing Clinicians, Patients, or Policies?

659 Global Health

Preventing Interpersonal Violence

Neonatal HBV Vaccine Protects Against Liver Disease

Closer to an Effective Ebola Vaccine

African Genome Variation Project Will Facilitate Genetic Studies in Africa

660 News From the CDC

Sickle Cell Disease Screening Offers Educational Opportunity for Parents

Knowing HIV Status Crucial in Cancer Treatment



Online @ jama.com



Editor's Audio Summary

Howard Bauchner, MD, summarizes and comments on this week's issue.

Author Reading



AUDIO John P. A. Ioannidis, MD, DSc, reads his Viewpoint "Stealth Research: Is Biomedical Innovation Happening Outside the Peer-Reviewed Literature?"

Author Interview

VIDEO Interview with Jon O. Ebbert, MD, author of "Effect of Varenicline on Smoking Cessation Through Smoking Reduction: A Randomized Clinical Trial"

Audio Interview with Antoni Torres, MD, PhD, author of "Effect of Corticosteroids on Treatment Failure Among Hospitalized Patients With Severe Community-Acquired Pneumonia and High Inflammatory Response: A Randomized Clinical Trial"

Departments

647 Staff Listing

723 CME Questions

734 JAMA Network Abstracts

736 JAMA Peer Reviewers in 2014

753 Classified Advertising

756 Journal Advertiser Index

757 Contact Information

Instructions for Authors

jama.com/public /instructionsforauthors.aspx